Mar 18, 2008 -- Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) (the "Company"), a biopharmaceutical and medical device company focused on infectious disease and dermatology, announced that preclinical testing of the Company's CeraShield(TM) coated endotracheal tubes and C.R. Bard's recently FDA cleared Agento(TM) tube has shown that Cerashield(TM) coated endotracheal tubes were able to provide a 7 fold increase in the duration of antimicrobial protection compared to the recently cleared silver coated Agento(TM) tube from C.R. Bard. The CeraShield(TM) coated endotracheal tube was able prevent bacterial colonization and biofilm development for 21 days while C.R. Bard's Agento(TM) endotracheal tubes lost their ability to prevent bacterial colonization and biofilm development after 3 days when challenged with daily high inocula (10E6) of Pseudomonas aeruginosa. Bacterial growth on endotracheal tubes is a key component in the pathogenesis of Ventilator Associated Pneumonia ("VAP") which afflicts an estimated 250,000 patients each year and is associated with high morbidity ( 36,000 deaths) and added hospital costs of $4 billion in the U.S. alone... Ceragenix's Press Release -
Apr 9, 2008
Ceragenix Pharmaceuticals : CeraShield(TM) Coated Endotracheal Tubes Provide up to 21 Days of Protection against Bacterial Colonization in Preclinical
Mar 18, 2008 -- Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) (the "Company"), a biopharmaceutical and medical device company focused on infectious disease and dermatology, announced that preclinical testing of the Company's CeraShield(TM) coated endotracheal tubes and C.R. Bard's recently FDA cleared Agento(TM) tube has shown that Cerashield(TM) coated endotracheal tubes were able to provide a 7 fold increase in the duration of antimicrobial protection compared to the recently cleared silver coated Agento(TM) tube from C.R. Bard. The CeraShield(TM) coated endotracheal tube was able prevent bacterial colonization and biofilm development for 21 days while C.R. Bard's Agento(TM) endotracheal tubes lost their ability to prevent bacterial colonization and biofilm development after 3 days when challenged with daily high inocula (10E6) of Pseudomonas aeruginosa. Bacterial growth on endotracheal tubes is a key component in the pathogenesis of Ventilator Associated Pneumonia ("VAP") which afflicts an estimated 250,000 patients each year and is associated with high morbidity ( 36,000 deaths) and added hospital costs of $4 billion in the U.S. alone... Ceragenix's Press Release -
